COMP <GO>
PRAX vs ARWR // EV/EBITDA & P/E VALUATION
Praxis Precision Medicines Inc. (NASDAQ) VS. Arrowhead Pharmaceuticals Inc. (NASDAQ) • 15-METRIC TALLY: PRAX 2
— ARWR 7
■ METRIC PARITY
LAST: $273.99 (-4.18%) • MKT CAP: $7.98B
valuation
—
LAST: $59.57 (-0.55%) • MKT CAP: $8.46B
valuation
73.8x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (PRAX VS. ARWR)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | PRAX | ARWR | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | 11.10% | -46.10 | ARWR | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | 73.8x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -3.09% | 1.84% | -4.93 | ARWR | /fcf-yield <GO> |
| Operating Margin | — | 11.90% | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | -0.20% | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | 8.80% | 180.00% | -171.20 | ARWR | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 26.00 | 6.60 | +19.40 | PRAX | /balance-sheet <GO> |
| Piotroski F-Score Quality | 5/9 | 8/9 | -3.00 | ARWR | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 54.5 | 41.3 | +13.20 | PRAX | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.91 | 0.96 | -0.05 | ARWR | /macro-sensitivity <GO> |
| Forward P/E Multiple | 33.0x | 18.0x | +15.00 | ARWR | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $7.98B | $8.46B | -$478.0M | ARWR | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | PRAX REV | ARWR REV | PRAX GROSS % | ARWR GROSS % | PRAX FCF | ARWR FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $913.4M | $829.4M | — | — | -$249.1M | $156.9M |
| FY 2024 | $8.6M | $3.6M | — | — | -$131.8M | -$604.3M |
| FY 2023 | $2.4M | $240.7M | — | — | -$111.2M | -$164.7M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
PRAX // BETA 0.91
ARWR // BETA 0.96